UK Markets closed

Celyad Oncology SA (0QFK.L)

LSE - LSE Delayed price. Currency in EUR
Add to watchlist
3.9400+0.0150 (+0.38%)
At close: 8:52AM BST
Full screen
Previous close3.9250
Open3.9400
Bid0.0000 x 0
Ask0.0000 x 0
Day's range3.9400 - 3.9400
52-week range3.9400 - 3.9400
Volume150
Avg. volumeN/A
Market cap47.762M
Beta (5Y monthly)1.48
PE ratio (TTM)N/A
EPS (TTM)-1.2560
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Globe Newswire

    Celyad Oncology Presents Updates on Allogeneic CAR T Clinical Candidates and shRNA-based Preclinical Concepts at Research & Development Day

    Phase 1 IMMUNICY-1 trial evaluating CYAD-211 in relapsed/refractory multiple myeloma (r/r MM) showed dose dependent engraftment up to dose level three (300×106 cells per infusion) with no Graft-versus-Host disease reported to dateSubmission of IND application for CYAD-203, a new first-in-class shRNA-based allogeneic, IL-18-armored CAR T candidate, expected in mid-2022CYAD-101 following FOLFIRI preconditioning in advanced metastatic colorectal cancer (mCRC) was well-tolerated; cell kinetic and ac

  • Globe Newswire

    Celyad Oncology to Host Virtual Research & Development Webinar on July 20th

    MONT-SAINT-GUIBERT, Belgium, July 13, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced it will host a Research & Development webinar on Tuesday, July 20th at 11:30 a.m. EDT. Members of the Celyad Oncology leadership team will provide an overview of the recent advances in the R&D pipeline including insights into new

  • Globe Newswire

    Celyad Oncology to Participate at the William Blair Biotech Focus Conference 2021

    MONT-SAINT-GUIBERT, Belgium, July 07, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that Chief Scientific Officer, Dr. David Gilham, will participate in a panel discussion titled “Cell Therapies in the Next Decade” to be held on Wednesday, July 14th, at 08:55 a.m. EST at the William Blair Biotech Focus Conferenc